Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

References for PMC Articles for PubMed (Select 20959004)

1.

Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials.

Koup RA, Lamoreaux L, Zarkowsky D, Bailer RT, King CR, Gall JG, Brough DE, Graham BS, Roederer M.

J Virol. 2009 Jun;83(12):6318-22. doi: 10.1128/JVI.00384-09. Epub 2009 Apr 1.

2.

Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.

Hamilton MM, Byrnes GA, Gall JG, Brough DE, King CR, Wei LL.

Mol Vis. 2008;14:2535-46. Epub 2008 Dec 30.

3.

Expression of pIX gene induced by transgene promoter: possible cause of host immune response in first-generation adenoviral vectors.

Nakai M, Komiya K, Murata M, Kimura T, Kanaoka M, Kanegae Y, Saito I.

Hum Gene Ther. 2007 Oct;18(10):925-36.

PMID:
17907966
4.

Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes.

Gall JG, Lizonova A, EttyReddy D, McVey D, Zuber M, Kovesdi I, Aughtman B, King CR, Brough DE.

Mol Biotechnol. 2007 Mar;35(3):263-73.

PMID:
17652790
5.

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.

Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2007 May;81(9):4654-63. Epub 2007 Feb 28.

6.

Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR, Gall JG.

Vaccine. 2007 Mar 1;25(11):2074-84. Epub 2006 Nov 28.

7.

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.

Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, van Meerendonk M, van der Vlugt R, Holterman L, Hone D, Skeiky Y, Mintardjo R, Gillissen G, Barouch D, Sadoff J, Goudsmit J.

J Gen Virol. 2006 Aug;87(Pt 8):2135-43.

8.

Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.

Ophorst OJ, Radosević K, Havenga MJ, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M.

Infect Immun. 2006 Jan;74(1):313-20.

9.

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2005 Aug;79(15):9694-701.

10.

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.

Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, Vogels R, Bakker M, Berkhout B, Havenga M, Goudsmit J.

AIDS. 2004 May 21;18(8):1213-6.

PMID:
15166541
11.

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J.

J Immunol. 2004 May 15;172(10):6290-7.

12.

Human adenovirus type 35: nucleotide sequence and vector development.

Gao W, Robbins PD, Gambotto A.

Gene Ther. 2003 Nov;10(23):1941-9.

PMID:
14528318
13.

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M.

J Virol. 2003 Aug;77(15):8263-71.

14.

Development of adenovirus serotype 35 as a gene transfer vector.

Seshidhar Reddy P, Ganesh S, Limbach MP, Brann T, Pinkstaff A, Kaloss M, Kaleko M, Connelly S.

Virology. 2003 Jul 5;311(2):384-93.

PMID:
12842627
15.

Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector.

Sakurai F, Mizuguchi H, Hayakawa T.

Gene Ther. 2003 Jun;10(12):1041-8.

PMID:
12776162
16.

Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus.

Nan X, Peng B, Hahn TW, Richardson E, Lizonova A, Kovesdi I, Robert-Guroff M.

Gene Ther. 2003 Feb;10(4):326-36.

PMID:
12595891
17.

Rapid construction of adenoviral vectors by lambda phage genetics.

McVey D, Zuber M, Ettyreddy D, Brough DE, Kovesdi I.

J Virol. 2002 Apr;76(8):3670-7.

18.
19.

Several E4 region functions influence mammary tumorigenesis by human adenovirus type 9.

Thomas DL, Schaack J, Vogel H, Javier R.

J Virol. 2001 Jan;75(2):557-68.

20.

Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products.

Christ M, Louis B, Stoeckel F, Dieterle A, Grave L, Dreyer D, Kintz J, Ali Hadji D, Lusky M, Mehtali M.

Hum Gene Ther. 2000 Feb 10;11(3):415-27.

PMID:
10697116
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk